Globe Newswire

Open Collage in a new Window

Make changes yourself !

NASDAQ OMX introduces DIY GlobeNewswire at NIRI annual conference

Order: Reorder
Duration: 1:47
Updated: 27 Aug 2010

Demetrios N. Skalkotos, senior vice president of Global Corporate Solutions, NASDAQ OMX, and Jeff Stacey, vice president of operations for Globe Newswire, ta...

http://wn.com/NASDAQ_OMX_introduces_DIY_GlobeNewswire_at_NIRI_annual_conference

ABN Newswire Australian Market Report Nov 22, 2010: Globe Metals & Mining (ASX:GBE) HREE Discovery

Order: Reorder
Duration: 1:52
Updated: 22 Nov 2010

Globe Metals and Mining Limited (ASX:GBE) reported laboratory chemical results for the maiden RC drilling program at the Machinga Rare Earth Project in south...

http://wn.com/ABN_Newswire_Australian_Market_Report_Nov_22,_2010_Globe_Metals_Mining_ASXGBE_HREE_Discovery

Northrop Grumman - Two X-47B UCAS Completed Air Worthiness Test Phase [720p]

Order: Reorder
Duration: 1:35
Updated: 01 Aug 2013

SAN DIEGO, June 14, 2012 (GLOBE NEWSWIRE) -- The first major phase of flight testing the X-47B Unmanned Combat Air System (UCAS) demonstrator aircraft came t...

http://wn.com/Northrop_Grumman_Two_X-47B_UCAS_Completed_Air_Worthiness_Test_Phase_720p_

Ingalls Shipbuilding - Arlington (LPD 24) Successfully Completes US Navy Acceptance Trials [720p]

Order: Reorder
Duration: 0:57
Updated: 30 Jun 2013

PASCAGOULA, Miss., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) announced today that the amphibious transport dock Arlington (LP...

http://wn.com/Ingalls_Shipbuilding_Arlington_LPD_24_Successfully_Completes_US_Navy_Acceptance_Trials_720p_

Northrop Grumman - X-47B UCAS First Cruise Flight [720p]

Order: Reorder
Duration: 1:33
Updated: 06 Aug 2013

Gear Up! U.S. Navy/Northrop Grumman X-47B Demonstrator Flies in Cruise Mode for First Time. EDWARDS AIR FORCE BASE, Calif., Oct. 10, 2011 (GLOBE NEWSWIRE) --...

http://wn.com/Northrop_Grumman_X-47B_UCAS_First_Cruise_Flight_720p_

THE ONE STOCK TO BUY BEFORE 2014!!! (NPWZ) EMERGENCY STOCK ALERT!!!

Order: Reorder
Duration: 2:08
Updated: 27 Nov 2013

THE ONE AND ONLY STOCK TO BUY BEFORE 2014!!! (NPWZ) EMERGENCY STOCK ALERT!!! - NEAH POWER SYSTEMS INC. - TOP RATED STOCKS - BEYOND THE GRID STOCKS - NEAH POWER (NPWZ) STOCK STRONG BUY Neah Power Systems Completes Asset Acquisition of Fuel Cell Business Enabling New Market Opportunities Newly Acquired Assets Bolster Neah Power's Current Product Line-Up and Opens Up New Markets in the Energy Market BOTHELL, Wash., Nov 26, 2013 (GLOBE NEWSWIRE via COMTEX) -- Neah Power Systems, Inc., (OTCBB:NPWZ) http://www.neahpower.com, a provider of power solutions using proprietary, award winning technology for the military, transportation, and portable electronics markets using the PowerChip(R) and the Buzz Bar technologies, announced today that the Company has completed a fuel cell technology asset acquisition that bolsters its current product line up, and opens up new market opportunities in the renewable energy sector. Neah Power Systems, Inc. (the "Company") issued 23,198,600 restricted common shares at a price of $0.019 per share, to Clean Tech Investors LLC (the "Seller") for a purchase price of $440,000 pursuant to the terms of an Asset Purchase Agreement. "This is an exciting time," said Dr. Chris D'Couto, CEO of Neah Power Systems. "The integration of this technology, intellectual property, and physical assets into the Company's suite of product offerings, strengthens our value proposition in the renewable energy marketplace, and opens up new avenues. We will continue to update shareholders on an ongoing basis on the new opportunities enabled by this asset purchase." Bill Shenkin, Manager of Clean Tech Investors LLC, noted, "We are pleased to combine these assets which were developed using an excess of $15M into Neah Power Systems. We believe that the ongoing commercial success of Neah Power Systems will provide a pathway to commercialize the assets that we bring to the table." As part of this asset purchase and previously announced investment by Clean Tech Investors LLC, Mr. Shenkin will be joining the Board of Directors of Neah Power Systems. About Neah Power Neah Power Systems, Inc. (NPWZ.OB) is an innovator of cutting-edge power solutions for the military, transportation and portable electronics industries. Neah Power's long-lasting, efficient, and safe solutions include patent-pending micro fuel cells that enable higher power densities in compact form-factors at a lower cost, and that run in aerobic and anaerobic modes. Neah Power was a 2012 ZINO Green Finalist, 2010 WTIA Finalist, and 2010 Best of What's New Popular Science Award. Contact Neah Power at (425) 424.3324 ext-108 or info@NeahPower.com. Neah Power has named Hitman, Inc., as their current agency of record. Forward Looking Statements Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements," which are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, and the Company does not undertake any responsibility to update any of these statements in the future. Please read Neah Power System's Form 10-K for the fiscal year ended September 30, 2012 and its Quarterly Reports on Form 10-Q filed with the SEC during fiscal 2013 for a discussion of such risks, uncertainties and other factors. CONTACT: Media Contact: Steve Brazell Hitman, Inc. | (212) 300.6026 steve@yourhitman.com http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwNTk1MDgjMjg5MDk= KEYWORD: BOTHELL, Wash. INDUSTRY KEYWORD: Energy Industries SUBJECT CODE: Mergers and Acquisitions ENERGY ACQUISITIONS Top 10's Lists and How To Videos

http://wn.com/THE_ONE_STOCK_TO_BUY_BEFORE_2014!!!_NPWZ_EMERGENCY_STOCK_ALERT!!!

Spine Pain Management Inc.2013 1st Quarter Conference Call

Order: Reorder
Duration: 79:44
Updated: 15 May 2013

Spine Pain Management, Inc. delivers a turnaround quarter, Spine Pain Management Reports 1st Quarter 2013 Financial Results; Conference Call to Follow at 4:1...

http://wn.com/Spine_Pain_Management_Inc2013_1st_Quarter_Conference_Call

DS Healthcare Group Files Patent for Prescription Hair Loss Treatment

Order: Reorder
Duration: 1:38
Updated: 29 Oct 2013

Pompano Beach, Oct. 29, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced it has filed a patent application titled, "Compositions and Methods for Treatment of Hair Loss," with the United Stated Patent and Trademark Office. The patent application addresses DS Healthcare's proprietary formulations that stimulate hair growth and reduce hair loss in men and women through treatments delivered topically. "We believe there is tremendous unmet demand for an effective prescription grade hair loss treatment. Although a few other prescription products have been launched for this indication in the past decades, they have either been less effective than users would prefer, or have been coupled been side effects that most users have found to be unacceptable," stated DS Healthcare President and CEO Daniel Khesin. "Having already generated millions of dollars providing over-the-counter shampoos and other topical hair growth products, we know this market and we believe our proprietary prescription-grade formulation holds promise for the millions of people looking to preserve their hair growth." About DS Healthcare Group DS Healthcare Group Inc. leads in the development of biotechnology for topical, and nutritional therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisReserachLabs.com) and The Pure Guild (www.ThePureGuild.com).

http://wn.com/DS_Healthcare_Group_Files_Patent_for_Prescription_Hair_Loss_Treatment

Pluristem Approved to Extend Phase II Study of PLX-PAD Cells to South Korea

Order: Reorder
Duration: 1:20
Updated: 13 Nov 2013

HAIFA, Israel, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the South Korean Ministry of Food and Drug Safety (MFDS), formerly the Korea Food & Drug Administration (KFDA), has approved Pluristem's Investigational New Drug (IND) Application to conduct a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). The IND approved by the MFDS mirrors INDs already approved by regulators in the USA, Germany and Israel. South Korea will be the fourth country participating in this multi-national trial involving the use of PLX-PAD in IC. CHA Bio&Diostech; Co., Ltd. (KOSDAQ:KS), Pluristem's South Korean partner, will fund the trial and conduct it in its healthcare facilities. "Pluristem's ability to extend our Phase II study of IC into South Korea is important for several reasons," commented Zami Aberman, Pluristem's Chairman and CEO. "Partnering with CHA Bio to conduct the clinical trial in their hospitals will accelerate the enrollment and strengthen our relationship with our South Korean partner. Additionally, Pluristem is proud of the fact that our PLX-PAD cells are the first placental-derived allogeneic cells allowed to be imported into South Korea. We at Pluristem believe this is a validation of Pluristem's expertise in cell therapy in general and PLX potential cell therapy in particular." About the Study Pluristem's Phase II study of IC is a randomized, placebo-controlled trial that will evaluate the safety and efficacy of two courses of PLX-PAD cells versus placebo, administered via intramuscular injections. The study protocol targets enrollment of 150 patients with IC: Fontaine class IIb, Rutherford category 2-3. The primary efficacy end point of the trial is the change in the maximal walking distance from baseline during an exercise treadmill test. Secondary endpoints are hemodynamic and quality of life measurements. Safety parameters are also being assessed. About Intermittent Claudication IC is a subset of PAD caused by atherosclerosis of the lower extremity arteries. IC is characterized by muscle pain, such as aching, cramping, numbness or a sense of fatigue classically in the calf muscle, which occurs during exercise, such as walking, and is relieved by a period of rest. The prevalence of IC in the United States alone is approximately 14 million patients and representing a cost of approximately $2.5 billion annually to the National Healthcare Bill (References:The SAGE Group and HCUP 2007 Inpatient Data). About CHA Bio&Diostech; CHA Bio&Diostech; Co., Ltd. is a leading biopharmaceutical company headquartered in South Korea; its R&D; focuses on stem cells, cell therapeutics, medical device, and new drug development. The company is a member of CHA Health Systems Group, which is comprised of a medical university, medical centers and hospitals located in the US and Korea with in excess of two thousand beds under care, stem cell research centers, personal & preventive medicine, and bio venture divisions. CHA Bio&Diostech; has multiple stem cell R&D; pipelines in therapeutic areas including Stargardt's disease, age-related macular disease, Parkinson's disease, Alzheimer disease, Cerebral Palsy and glioblastoma in mid- to late-stages of development. With its extensive experience and research infra structure, CHA Bio&Diostech; has built up multiple strategic relations with major research institutions in the fields of stem cell research and infertility. For more information visit www.chabio.com, the content of which is not part of this press release. About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

http://wn.com/Pluristem_Approved_to_Extend_Phase_II_Study_of_PLX-PAD_Cells_to_South_Korea

Receivables Financing Programs for Staffing Companies

Order: Reorder
Duration: 2:36
Updated: 03 Jul 2013

Receivables Financing Programs for Staffing Companies If you are a staffing company, you know that making payroll is one of the more significant challenges f...

http://wn.com/Receivables_Financing_Programs_for_Staffing_Companies

Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model

Order: Reorder
Duration: 1:49
Updated: 05 Nov 2013

HAIFA, Israel, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that its PLacental eXpanded (PLX) cells proved to be safe in an animal study assessing maternal and fetal toxicity. The study was conducted at the Charles River Laboratories, one of the world's leading contract research organizations. The results showed that the intramuscular administration of PLX-PAD cells to pregnant rats did not result in any maternal or fetal toxicity. Pluristem will pursue the clinical development of PLX-PAD cells for the indication of preeclampsia based on these results and earlier evidence that the cells were efficacious in preeclamptic animal models. "Pluristem is extremely pleased with the demonstrated safety of our PLX-PAD cells in pre-clinical models of pregnancy," said Zami Aberman, Chairman and CEO of Pluristem. "This study, together with the work performed by Dr. Brett Mitchell from Texas A&M; College of Medicine,suggesting that our PLX-PAD cells are efficacious in preeclamptic animal models, is an important milestone towards our goal of initiating clinical trials for preeclampsia." In the study, forty-four pregnant female rats were injected intramuscularly with either PLX-PAD at a dosage of 10 million cells (n=22) or cell-free placebo (n=22), on gestational day 13. Throughout the study the pregnant animals were monitored for viability status, body weight and food consumption. On gestational day 21, female rats were examined for ovarian and uterine contents and abnormalities in dams and pups. Charles River's report concluded that the IM injection of PLX-PAD cells in pregnant rats did not result in any maternal or fetal developmental toxicity. About Preeclampsia Preeclampsia is one of the most common medical complications of pregnancy, and one of the leading causes of premature births, stillbirths and early neonatal and maternal deaths. If left untreated, it can progress to eclampsia, the life-threatening occurrence of seizures during pregnancy. The only known treatment for preeclampsia is abortion or delivery. The disease occurs in previously healthy women after their 20th week of pregnancy, and signs include high blood pressure and significant amounts of protein in the urine. According to the World Health Organization, preeclampsia occurs in approximately 6--8% of pregnancies worldwide. It is estimated that preeclampsia costs the global health care system $3 billion annually. About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

http://wn.com/Safety_of_Pluristem's_PLX_Cells_Demonstrated_in_Pre-Clinical_Pregnancy_Model

Pluristem Receives Approval to Expand Its Phase II Clinical Trial to Israel

Order: Reorder
Duration: 1:07
Updated: 02 Oct 2013

HAIFA, Israel, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Israeli Ministry of Health has approved the company's request to initiate a Phase II study using its PLacental eXpanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). This approval is part of the company's previously announced strategy to conduct a multi-national study for this indication. The protocol will be the same one used for the study previously approved in the U.S. Zami Aberman, Chairman and CEO of Pluristem stated, "We are excited to receive the Ministry of Health approval for our clinical study in Israel. This also marks the first clinical study in Israel to use off-the-shelf allogeneic, placental-derived cells. Additionally, the professional review of this clinical trial application by the Israeli Ministry of Health will provide a solid foundation for Pluristem to conduct additional studies in Israel." About the Study Pluristem's IC Phase II is a randomized, placebo-controlled trial that will evaluate the safety and efficacy of two doses of PLX-PAD cells versus placebo, administered via intramuscular injections. The study protocol is comprised of approximately 150 patients with IC: Fontaine class IIb, Rutherford category 2-3. The primary efficacy end point of the trial is the change in the maximal walking distance from baseline during an exercise treadmill test. Secondary endpoints are hemodynamic and quality of life measurements. Safety parameters are also being assessed. About Intermittent Claudication IC is a subset of PAD caused by atherosclerosis of the lower extremity arteries. IC is characterized by muscle pain, such as aching, cramping, numbness or a sense of fatigue classically in the calf muscle, which occurs during exercise, such as walking, and is relieved by a period of rest. The prevalence of IC in the United States alone is approximately 14 million patients and representing a cost of approximately $2.5 billion annually to the National Healthcare Bill (References:The SAGE Group and HCUP 2007 Inpatient Data). About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

http://wn.com/Pluristem_Receives_Approval_to_Expand_Its_Phase_II_Clinical_Trial_to_Israel

NNS - USS Theodore Roosevelt (CVN 71) Sea Trials After Refueling & Complex Overhaul [1080p]

Order: Reorder
Duration: 2:29
Updated: 03 Oct 2013

NEWPORT NEWS, Va., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Newport News Shipbuilding (NNS), a division of Huntington Ingalls Industries (NYSE:HII), redelivered the nuclear-powered aircraft carrier USS Theodore Roosevelt (CVN 71) to the U.S. Navy today. The redelivery took place following successful sea trials that tested the ship's systems after its refueling and complex overhaul (RCOH) at the shipyard. The sea trials, conducted by the U.S. Navy alongside NNS shipbuilders onboard, tested the carrier's systems and operations at sea, including high-speed operations. The trials team put the ship through a series of tests designed to prove system performance and demonstrate all the carrier's capabilities at sea. "The ship's refueling and modernization was an enormous undertaking made successful by the joint efforts of the shipyard, Navy and government team," said Chris Miner, NNS' vice president, in-service aircraft carrier programs. "Her strong performance during sea trials is a source of pride for the 4,000 shipbuilders who worked tirelessly to return Roosevelt to the Navy's operational fleet today." The RCOH process is performed only once during the ship's 50-year lifetime and involves upgrades to nearly every space and system on the ship. Tanks, the hull, shafting, propellers, rudders, piping, ventilation, electrical, combat and aviation support systems were repaired, upgraded and modernized. Work also included defueling and refueling the ship's two nuclear reactors and repairs and upgrades to the propulsion plant. NNS is the only shipyard with the skilled workforce and facilities equipped for this nearly four-year project, which was described in a 2002 Rand Study as one of the most challenging and highly industrial tasks undertaken by any organization. The fourth Nimitz-class carrier to undergo an RCOH, Roosevelt has had up to 4,000 shipbuilders assigned to her at peak manning periods. USS Abraham Lincoln (CVN 72) arrived at NNS in March and is currently undergoing her RCOH.

http://wn.com/NNS_USS_Theodore_Roosevelt_CVN_71_Sea_Trials_After_Refueling_Complex_Overhaul_1080p_

Tendon Injuries Treated With Pluristem's PLX Cells Demonstrate Favorable Properties

Order: Reorder
Duration: 1:50
Updated: 15 Aug 2013

HAIFA, Israel, Aug. 14, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the results of a pre-clinical trial using the Company's PLacental eXpanded (PLX) cells in tendon injury. Dr. Scott Rodeo and his orthopedic research team at New York's Hospital for Special Surgery (HSS) studied the effects of PLX cells on rat patellar tendons that had sustained collagenase-induced injuries. "Cell-based approaches clearly have great potential for the augmentation of connective tissue healing, as well as for tissue regeneration. As an 'off the shelf' cell source, PLX cells could provide an effective option to improve tendon healing," stated Scott Rodeo MD, Principal Investigator for this study and Professor of Orthopedic Surgery at Weill Cornell Medical College. Dr. Rodeo is Co-Chief of the Sports Medicine and Shoulder Service at Hospital for Special Surgery, New York; Associate Team Physician for the New York Giants Football Team; and Physician for the U.S.A. Olympic Swimming Team. "Pluristem is extremely pleased that the results of this pre-clinical trial validate our strategy to pursue the use of our PLX cells for tendon injuries and other orthopedic indications. We look forward to the results of our recently fully-dosed, Phase I/II clinical trial in Germany using our PLX cells in muscle injury," stated Zami Aberman, Chairman and CEO of Pluristem. PLX-treated tendons demonstrated better early structural properties at 2 and 4 weeks compared to saline-treated controls. This was evident based on statistically significant higher load-to-failure properties at 2 weeks following injection. Additionally, the demonstrated higher mean load-to-failure and stiffness properties were maintained at 4 weeks. These improved biomechanical properties may be related to the findings of a greater proteoglycan and collagen content seen at the tendon-bone interface of PLX-treated samples. About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

http://wn.com/Tendon_Injuries_Treated_With_Pluristem's_PLX_Cells_Demonstrate_Favorable_Properties

FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study

Order: Reorder
Duration: 1:52
Updated: 16 Sep 2013

HAIFA, Israel, Sept. 16, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on the Company's U.S. Phase II Intermittent Claudication (IC) study (IND 15038) on June 4, 2013. In its letter to Pluristem, the FDA indicated Pluristem had satisfactorily addressed all the clinical hold issues and the Company may proceed with the study. Zami Aberman, Pluristem's Chairman and CEO commented, "Pluristem applauds the FDA's vigor to resolve this clinical hold as quickly as possible. We look forward to resuming this important study that addresses the growing, costly and potential serious indication of intermittent claudication." About Pluristem's Phase II Intermittent Claudication (IC) Clinical Trial Pluristem's Phase II Intermittent Claudication (IC) study uses the Company's PLX-PAD cells. Up to 150 patients will be enrolled in this dose escalation, randomized, double blind, multicenter, multinational, placebo-controlled trial whose primary endpoints at 12 months will be safety and maximal walking distance relative to baseline. The study protocol will be modified by tightening patient's eligibility criteria and by adding oral anti-histamines and a safety follow-up period for 24 hours post study treatment. About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

http://wn.com/FDA_Lifts_Clinical_Hold_of_Pluristem's_Phase_II_Intermittent_Claudication_Study

Pluristem Awarded a $3.3 Million Grant by Israeli Government

Order: Reorder
Duration: 1:51
Updated: 08 Aug 2013

HAIFA, Israel, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 12 million New Israeli Shekels (approximately $3.3 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Once received, the grant will be used to cover R&D; expenses for the period January 2013 to December 2013. "We are grateful for the support of the Israeli Office of Chief Scientist, and their leadership in building the biotechnology sector into one of the leading industries in Israel," said Zami Aberman, Chairman and CEO of Pluristem. "This grant helps us to further advance our R&D; pipeline and to move new indications into our growing product portfolio clinical trials in the U.S., Israel and Europe. Pluristem's advanced and innovative manufacturing technology enables the mass production of PLX cells in our new facility. This allows Pluristem to support a variety of clinical trials and if and when PLX product candidates are approved for marketing, to supply PLX products to its partners. This competitive advantage is recognized by the OCS who promotes innovation and supports our progress and growth." About the Office of the Chief Scientist and grant terms The OCS, empowered by the Law for the Encouragement of Industrial Research & Development -- 1984, oversees all Government sponsored support of R&D; in the Israeli hi-tech and bio-tech industries. This broad-spectrum support stimulates the development of innovative state-of-the art technologies, enhances the competitive power of the industry in the global hi-tech market, creates employment opportunities and assists in improving Israel's balance of payments. According to the OCS grant terms, Pluristem Ltd. is required to pay royalties in the rate of 3% - 5% on sales of products and services derived from technology developed using this and other OCS grants until 100% of the dollar-linked grants amount plus interest are repaid. In the absence of such sales, no payment is required. About Pluristem Therapeutics Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. Data from two Phase I clinical trials indicate that Pluristem's first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage PAD. Pluristem's pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, multiple sclerosis, or MS, and stroke when administered systemically. Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release. Follow Pluristem on Twitter @Pluristem.

http://wn.com/Pluristem_Awarded_a_33_Million_Grant_by_Israeli_Government

Newport News Shipbuilding - USS Minnesota (SSN 783) Nuclear Submarine First Sea Trials [1080p]

Order: Reorder
Duration: 1:36
Updated: 17 Aug 2013

NEWPORT NEWS, Va., May 6, 2013 (GLOBE NEWSWIRE) -- Huntington Ingalls Industries (NYSE:HII) announced that the newest Virginia-class submarine, Minnesota (SS...

http://wn.com/Newport_News_Shipbuilding_USS_Minnesota_SSN_783_Nuclear_Submarine_First_Sea_Trials_1080p_

"Martin Didn't Die For This" EM3 (MLK)

Order: Reorder
Duration: 12:35
Updated: 14 Jun 2013

PHOENIX, April 3, 2012 (GLOBE NEWSWIRE) -- Pioneering light will be emitted from EM3 Productionz (ASCAP), a father and 2 sons premiere positive rap group who...

http://wn.com/Martin_Didn't_Die_For_This_EM3_MLK

DS Healthcare Group Launches Brazilian E-Commerce Site

Order: Reorder
Duration: 1:37
Updated: 12 Sep 2013

Pompano Beach, Sept. 11, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced it has launched its Brazilian website: http://dslabshop.com.br. The e-commerce site provides convenient online shopping for Brazilians. The site also offers extensive product information to support in-stores sales of its products. DS Healthcare recently expanded the distribution of its products into Brazil's CSB Drogaria which operates two retail pharmacy chains, Drogasmil and Farmalife with stores primarily located in the Rio de Janeiro metropolitan area. "Our new e-commerce site in Brazil reaches the country's broader population. Our 10 best-selling SKUs approved for commercialization are currently being sold in the Brazilian market through retail stores in one key metropolitan area and we expect our national reach through e-commerce will further increase exposure and sales of our products," stated DS Healthcare President and CEO Daniel Khesin. "We've seen through our initial pilot programs that our product line, particularly our hair growth products are ideally suited for the Brazilian consumer." According to Euromonitor, a market research firm, the Brazilian beauty industry generated $43 billion in sales in 2011, an increase of 19% over the prior year. About DS Healthcare Group DS Healthcare Group Inc. leads in the development and distribution of topical therapies for personal care, including what management believes is the world's most effective topical treatment for hair loss. Its products are sold through a network of salons, pharmacies, online retailers, specialty retailers and select department stores. Its brands include DS Laboratories(www.DSLaboratories.com), Sigma Skin (www.(www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisResearchLabs.com) The Pure Guild (www.ThePureGuild.com) and Nutra Origin (www.NutraOrigin.com)

http://wn.com/DS_Healthcare_Group_Launches_Brazilian_E-Commerce_Site

DS Healthcare Group Expands Distribution Channels to Include $43 Billion Brazilian Beauty Market

Order: Reorder
Duration: 1:21
Updated: 06 Aug 2013

Pompano Beach, Aug 05, 2013 (GLOBE NEWSWIRE via COMTEX) -- DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced i...

http://wn.com/DS_Healthcare_Group_Expands_Distribution_Channels_to_Include_43_Billion_Brazilian_Beauty_Market

Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft versus Host Disease

Order: Reorder
Duration: 2:27
Updated: 01 Oct 2013

HAIFA, Israel, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company's PLacental eXpanded (PLX) cells demonstrated efficacy in a preliminary animal experiment for the treatment of Graft versus Host Disease (GvHD) following bone marrow transplantation (BMT). The results showed that PLX cells, regardless of their administration route, intravenous (IV) or intramuscular (IM), demonstrated a statistically significant improvement GvHD may occur after BMT when patients receive bone marrow tissue or cells from a donor and these newly transplanted cells regard the recipient's body as foreign, attacking the recipient's body. The global incidence of acute GvHD ranges from 26% to 34% in recipients of fully matched sibling donor grafts, to 42% to 52% in recipients of matched unrelated donor grafts. The animal study was conducted in the laboratories of the Department of Bone Marrow Transplantation, Hadassah Medical Center, the Hebrew University, Jerusalem. In the study, mice underwent total body irradiation and after twenty-four hours received a semi-allogeneic BMT. PLX cells, or the same volumes of the control vehicle, were then injected IV or IM into the mice concurrently with the BMT (day 0, ~20h after irradiation) and 5 days post-irradiation. PLX markedly reduced the GvHD score, comprised of weight loss, diarrhea, skin and fur integrity and survival. "Based on the results of this pre clinical study suggesting our PLX cells may be effective in GvHD, we are pleased with the interest of leading medical institutions to use our PLX cells and will consider a cooperation to advance into a clinical program for this indication," said Zami Aberman, Chairman and CEO of Pluristem. "This indication would be complementary to the other indications we plan to pursue in the hematology field. Additionally, this study also gives Pluristem another data point demonstrating PLX cells do not have to be given intravenously to obtain a systemic effect." IM Administration with Systemic Effect This preclinical study marks the second time that the IM administration of PLX cells has demonstrated a systemic effect with efficacy in a hematological disease and the fourth time when preclinical animal models for other indications are included. Pluristem previously reported that the IM injection of PLX cells demonstrated a systemic effect in preclinical studies of Peripheral Artery Disease (PAD), Preeclampsia and Acute Radiation Sickness (ARS). Additionally, systemic, beneficial effects were also noted in three patients given PLX cells IM compassionately for Bone Marrow Failure. About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

http://wn.com/Pluristem's_PLX_Cells_Demonstrate_Efficacy_in_Preclinical_Study_for_Graft_versus_Host_Disease

DS Healthcare Group (DSKX) Reports Second Quarter 2013 Results

Order: Reorder
Duration: 2:12
Updated: 20 Aug 2013

Pompano Beach, Aug. 20, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced results for the three and six months ended June 30, 2013. Net revenues increased 35% for the first six months of 2013 to $7,392,846, over revenues of $5,482,244 in the same period of 2012. Revenue growth was primarily due to the acquisition of the Company's Mexican subsidiary and carryover of unfilled orders from the fourth quarter of 2012. Gross profits for the six months ended June 30, 2013 increased by 35% to $3,375,769 as compared to $2,501,081 in the same period of 2012. Net loss attributable to shareholders during the six months ended June 30, 2013 was $(1,125,056) or $(0.10) per basic and diluted share, as compared to $(808,423) or $(0.08) per basic and diluted share in the same period of 2012. Net revenues for the second quarter of 2013 were $3,431,154, a 2% decline from revenues of $3,498,262 in the second quarter of 2012. Revenues decreased slightly due to the Company's new policies related to extending credit to new and existing customers, preventing the Company from shipping some goods on its schedule. Gross profits increased by 10% to $1,601,087 in the second quarter of 2013, as compared to $1,450,761 in the second quarter of fiscal 2012. Net loss attributable to shareholders in the second quarter of 2013 was $(757,063) or $(0.06) per basic and diluted share as compared to $(368,086) or $(0.03) per basic and diluted share in the second quarter of 2012. . The Company reported total current assets of $8,042,076 and total shareholders' equity of $3,204,332 on June 30, 2013. "In the first half of 2013 we have achieved record revenues. We continue to launch new products and expand further into promising new markets like Brazil, through our distribution partner and Mexico, through our newly acquired Mexican subsidiary. There is tremendous enthusiasm in the market for our products and we strive to deliver more products to more people to meet their needs. Our customers have a passion for our products because they are extremely effective. We reported results from a clinical study we concluded during the second quarter which showed that our Spectral.DNC-S is effective in the promotion of healthy hair and in the cessation of thinning hair in males. We are optimistic about the remainder of 2013 as we continue to execute on a tremendous market opportunity," stated DS Healthcare President and CEO Daniel Khesin. About DS Healthcare Group DS Healthcare Group Inc. leads in the development and distribution of topical therapies for personal care, including what management believes is the world's most effective topical treatment for hair loss. Its products are sold through a network of salons, pharmacies, online retailers, specialty retailers and select department stores. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.(www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisResearchLabs.com) The Pure Guild (www.ThePureGuild.com) and Nutra Origin (www.NutraOrigin.com)

http://wn.com/DS_Healthcare_Group_DSKX_Reports_Second_Quarter_2013_Results

Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease..Sept 11, 2013

Order: Reorder
Duration: 1:43
Updated: 11 Sep 2013

Pluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease Exclusive Rights to Treat PAD With Placental Cells in the U.S. HAIFA, Israel, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has completed a major step in its intellectual property strategy: the United States Patent and Trademark Office has granted the Company U.S. Patent 8,529,888. This patent, the 26th issued to the Company, covers methods for the treatment of peripheral artery disease with placental-derived adherent stromal cells. The treatment for PAD is one of Pluristem's primary drug development areas. Based on priority date, the expected expiration date of this patent is at least until 2028. "This patent is an important milestone in Pluristem's intellectual property strategy and brings us closer to realizing our vision - to become a world leader in developing and manufacturing cell therapy products," said Zami Aberman, Chairman and CEO of Pluristem. "We believe it is a key asset and significantly enhances our competitive position in cell therapy-based therapeutics." About PAD Peripheral artery disease (PAD) is a decrease in blood flow to the lower extremities due primarily from cholesterol plaque blocking the arteries to these limbs. The disease is frequently seen in patients with diabetes and can result in lower extremity ulcers and amputations. Approximately 18 million people in the in the U.S. suffer from PAD with the resultant economic burden estimated to average approximately $200B annually. Current therapeutic methodologies have proven ineffective for many patients with severe PAD and has led to the medical community's call for the development of cell therapies, such as Pluristem's PLX-PAD, as an alternative and potentially cost-effective treatment. About Pluristem's Intellectual Property Approach Pluristem's IP portfolio currently includes 26 issued patents and about 100 worldwide pending patent applications fully owned by the company. Pluristem has developed a Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

http://wn.com/Pluristem_Granted_Key_US_Patent_for_the_Treatment_of_Peripheral_Artery_DiseaseSept_11,_2013

photo: WN / Janice Sabnal

The grocery section of Walmart Supercentre in Victoria, British Columbia, Canada as seen on this June 9, 2011 photo.

Edit

2013 Walmart holiday hours: Christmas hours for Walmart, Target, Toys R Us, more

The Examiner

24 Dec 2013

If you need to do last-minute Christmas shopping, check the list below for Walmart holiday hours and Christmas Eve closing times; Target holiday hours; Toys R Us closing time and information on the store closing times at other popular retailers nationwide. (Store hours list below). With just hours to go before Santa arrives, shoppers are hoping to score a last-minute bargain on Dec. 24, 2013 ... Order by 2 p.m ... at most stores) ... - 6 p.m. KMart....(size: 2.3Kb)

photo: AP / Kyodo News

File - In this photo taken on April 15, 2012, North Korean leader Kim Jong Un, right, speaks with Vice Marshal Choe Ryong Hae during a mass military parade in Kim Il Sung Square to celebrate the centenary of the birth of his grandfather, national founder Kim Il Sung in Pyongyang, North Korea.

Edit

Kim tells N Korean army to ready for combat

Al Jazeera

25 Dec 2013

North Korean leader Kim Jong-Un has warned war could break out "without any prior notice" and urged his military to bolster its combat readiness, state media reported. The call on Wednesday comes one day after a US-Korea Institute at Johns Hopkins University report said that satellite imagery suggested that the North might have begun producing fuel rods for its recently restarted nuclear reactor ... 372 Source .. Al Jazeera and agencies. ....(size: 2.5Kb)

photo: US Army

U.S. Army Pfc. Reed Roalf from Headquarters and Headquarters Company, 1st Battalion, 325th Airborne Infantry Regiment, labels AK-47 assault rifles captured during Operation Bulldog Mammoth

Edit

Tupelo Shooting: Officer Killed With AK-47 Assault Rifle

The Inquisitr

25 Dec 2013

A passer-by, Kenny Steen, heard a racket coming from a pawn store in Tupelo. “We heard some, just a real, ‘burr, burr’ real fast, so we came out and there was cop cars coming they stopped right here in the street,” he said. He said he witnessed the moment the officer was shot ... “The law enforcement is leaving no stone unturned ... ....(size: 1.8Kb)

« back to news headlines

Edit

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Tri-Tech Holding ...

Stockhouse

27 Dec 2013

NEW YORK, Dec. 26, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons who purchased securities of Tri-Tech Holding Inc. ("Tri-Tech" or the "Company") (Nasdaq.TRIT) between March 26, 2012 and December 12, 2013....(size: 1.6Kb)

Edit

ALK announces FDA Advisory Committee to review ragweed sublingual AIT tablet (ALK-Abelló A/S)

noodls

27 Dec 2013

(Source. ALK-Abelló A/S). Copenhagen, 2013-12-26 23.18 CET (GLOBE NEWSWIRE) --. Allergenic Products Advisory Committee meeting scheduled for 28 January 2014. ALK (ALKB.DC / OMX ... FDA advisory committees are panels of independent experts who advise the agency as they consider regulatory decisions. Advisory committee meetings are open to the public and are common for new drug classes and/or major pharmaceutical drugs under review. ....(size: 3.7Kb)

Edit

RDA Microelectronics Announces the Receipt of Shareholder Approval for Acquisition by Tsinghua Unigroup Ltd.

Stockhouse

27 Dec 2013

SHANGHAI, China, Dec. 27, 2013 (GLOBE NEWSWIRE) -- RDA Microelectronics, Inc ... ("Tsinghua Unigroup") ... Approximately 70.70% of the outstanding ordinary shares (including ordinary shares underlying outstanding American depositary shares) voted at the EGM, with approximately 99.74% of such voted shares voting in favor of these resolutions. As such, the Merger was duly approved by the Company's shareholders ... About RDA Microelectronics ... CONTACT....(size: 4.4Kb)

Edit

LOMIKO METALS ARRANGES $100,020 PRIVATE PLACEMENT FINANCING (Lomiko Metals Inc)

noodls

27 Dec 2013

(Source. Lomiko Metals Inc) # 4 3 9 - 7 1 8 4 1 2 0 t h S t r e e t , S u r r e y , B . C . V 3 W 0 M 6. December 17, 2013 TSX-V. LMR NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR. DISSEMINATION IN THE UNITED STATES. Vancouver BC - LOMIKO METALS INC. (TSX-V. LMR, OTC....(size: 1.7Kb)

Edit

Filmmakers, actors with local ties figure in movie awards race

Sacramento Bee

27 Dec 2013

He’s been nominated for a Screen Actors Guild Award, a Golden Globe and is likely to draw a best-actor Oscar nomination for his performance as the captain of a hijacked merchant ship in “Captain Phillips.” ... It drew no SAG nor Globe nominations often good indicators of a film’s Academy Awards outlook ... The Globes are set to air Jan....(size: 3.4Kb)

Edit

Rahm Emmanuel set to discriminate against Chick-fil-A over religious views

The Examiner

27 Dec 2013

"You can’t have a business in the City of Boston that discriminates against a population,” he told the Boston Globe ... Even the Boston Globe asked ... "A business owner’s political or religious beliefs should not be a test for the worthiness of his or her application for a business license," the Globe added ... The Globe recognized that danger as well....(size: 4.8Kb)

Edit

Update on new ASX Ticker Code (Solimar Energy Limited)

noodls

27 Dec 2013

(Source. Solimar Energy Limited). A B N 42 112 256 649. w w w . s o l i m a r e n e r g y . c o m . a u December 23, 2013 RELEASE to TSXV and ASX. Update on new ASX Ticker Code. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Solimar Energy Limited ("Solimar" or "the Company") (ASX. SGY; TSXV ... For further information contact.. Jason Bednar - Director / Chris Bowyer - Company Secretary ... (noodl....(size: 3.4Kb)

Edit

Notice to repay Debentures maturing 31 December 2013 in Shares (Solimar Energy Limited)

noodls

27 Dec 2013

(Source. Solimar Energy Limited). ABN 42 112 256 649 www.solimarenergy.com.au December 24, 2013 RELEASE to ASX and TSXV. Notice to repay Debentures maturing 31 December 2013 in Shares. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Solimar Energy Limited (ASX. SGY; TSXV ... The Company will also be issuing an Appendix 3B updating on the issue of these shares on the ASX ... Reader Advisory ... (noodl....(size: 4.2Kb)

Edit

Couple wed 61 years get 'Up'-inspired wedding photos

The Los Angeles Times

27 Dec 2013

Donald and Dorothy Lutz were married more than 60 years ago, but they had only one snapshot to show for it. That's because their wedding photographer stood them up on their big day ... Also Dog saying goodbye to his dying master ... Read more about the couple and their love story at the Boston Globe ... Dorothy told the Globe that -- photos or no photos -- she got the best gift of all the day she married ... Christmas decorations around the globe ... 0 ... ....(size: 5.8Kb)

Edit

London theatre highlights 2014: critic's choice

London Evening Standard

27 Dec 2013

Shakespeare’s Globe, Jan 9-Feb 16. The Globe’s new indoor Sam Wanamaker Playhouse opens with Gemma Arterton in the title role of this sparkling Jacobean tragedy. shakespearesglobe.com. King Lear. National’s Olivier, from Tue Jan 14. Sam Mendes directs Simon Russell Beale in what is already the hottest theatrical ticket of 2014. nationaltheatre.org.uk. Blurred Lines. National’s Shed, Jan 16-Feb 22 ... With added songs. nationaltheatre.org.uk....(size: 2.4Kb)

Edit

Consolidation - New ASX Ticker Code - Share Interest Payment (Solimar Energy Limited)

noodls

27 Dec 2013

(Source. Solimar Energy Limited). A B N 42 112 256 649. w w w . s o l i m a r e n e r g y . c o m . a u December 20, 2013 RELEASE to TSXV and ASX. Share Consolidation in effect, new ASX Ticker Code and Share Interest Payment. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Solimar Energy Limited ("Solimar" or "the Company") (ASX. SGY; TSXV ... 25 existing Shares into one (1) new Share ... 1 ... (noodl....(size: 4.9Kb)

Edit

The Thinker: The Year That Was

Jakarta Globe

27 Dec 2013

By Yanto Soegiarto on 10.25 am December 27, 2013. Category Columns, Opinion. Tags. The Thinker. The year 2013 saw extraordinary happenings especially in corruption revelations and national politics ... The alarming level of graft by officialdom has painted a bleak picture of the government’s effectiveness ... Within the PDI-P, there are two camps ... Yanto Soegiarto is the managing editor of Globe Asia, a sister publication of the Jakarta Globe ... ....(size: 4.3Kb)

Edit

Kreyenhagen Update (Solimar Energy Limited)

noodls

27 Dec 2013

(Source. Solimar Energy Limited). A B N 42 112 256 649. w w w . s o l i m a r e n e r g y . c o m . a u December 23, 2013 RELEASE to ASX and TSXV. Kreyenhagen Update. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Solimar Energy Limited (ASX.SGY; TSXV.SXS) ("Solimar" or "the Company") has signed a Letter of Intent ... Agreement that was announced on May 7, 2013 ... Jason Bednar - Director....(size: 6.6Kb)

This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/GlobeNewswire

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.

This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Theodore_Roosevelt

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.